Feasibility of 18F-fluoromethylcholine PET/CT for imaging of vessel wall alterations in humans-first results
Feasibility of 18F-fluoromethylcholine PET/CT for imaging of vessel wall alterations in humans-first results
复制标题
DOI：
10.1007/s00259-007-0685-x
复制
发表时间：
2008-04-01
影响因子：
9.1
通讯作者：
Manka, Christoph
中科院分区：
文献类型：
--
作者：
Bucerius, Jan;Schmaljohann, Joern;Manka, Christoph
最近发表的数据表明，f -18-氟胆碱可用于动物模型中易损动脉粥样硬化斑块的成像。方法回顾性分析5例行f -18-氟甲基胆碱（F-18-FMCH-）全身PET/CT检查前列腺癌的临床资料。静脉注射F-18-FMCH后立即开始全身PET扫描。注射示踪剂后约5-15分钟，进行骨盆和腹部扫描。生成PET、CT和PET/CT切片，对腹主动脉和髂总动脉进行复查和视觉分析。在检查的动脉和周围结构中由于伪影的血管发现被排除在进一步的分析之外。F-18-FMCH摄取的下限设定在被检查血管内的背景活动之上。血管壁改变（WA）的形态学分类包括无附加钙化的结构壁改变（SWA）、钙化相关的结构壁改变（SWC）和单纯钙化病变（CL）。它们与F-18-FMCH摄取相关，反之亦然。结果共鉴定出31个WA。14个病灶中发现F-18-FMCH摄取阳性（SWA: n = 5; SWC: n = 9）。17个F-18-FMCH阴性病变中有16个被确定为CL，没有额外的血管壁结构改变。一个SWA没有显示任何F-18-FMCH积累。没有CLs以及未改变的血管壁部分显示F-18-FMCH摄取。我们对5例共31例血管壁改变的患者的初步数据显示了有希望的结果，首次表明F-18-FMCH用于人体结构WA的体内成像的可行性。
Purpose Recently published data indicated F-18-fluorocholine to be feasible for imaging vulnerable atherosclerotic plaques in an animal model.Methods Five patients undergoing whole-body F-18-fluoromethylcholine( F-18-FMCH-) PET/CT for imaging of prostate cancer disease were retrospectively evaluated. Whole-body PET scans were started immediately after i.v. injection of F-18-FMCH. About 5-15 min after tracer injection, acquisition of scans of the pelvis and abdomen was performed. PET, CT, and PET/CT slices were generated for review and visual analyses of the abdominal aorta and the common iliac arteries were performed. Vascular findings in examined arteries and surrounding structures due to artifacts were excluded from further analysis. The lower threshold of F-18-FMCH uptake was set above the background activity within the examined vessels. Morphological classification of vessel wall alterations (WA) included structural wall alterations without additional calcification (SWA), structural wall alterations associated with calcifications (SWC), and solely calcified lesions (CL). They were correlated with F-18-FMCH uptake qualified as present and vice versa.Results A total of 31 WA were identified. Positive F-18-FMCH uptake was found in 14 lesions (SWA: n = 5; SWC: n = 9). Sixteen of 17 F-18-FMCH negative lesions were identified as CL without additional structural vessel wall alteration. One SWA did not show any F-18-FMCH accumulation. None of the CLs as well as unaltered parts of the vessel wall showed F-18-FMCH uptake.Conclusions Our initial data in five patients with a total of 31 vessel wall alterations show promising results indicating for the first time the feasibility of F-18-FMCH for in vivo imaging of structural WA in humans.